Back to News
Dec 9, 2025 12:40 PM

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

The data showed encouraging anti-tumor responses and a manageable safety profile for pumitamig plus chemotherapy in first-line and second-line treatment settings.

The data will be presented at the 2025 San Antonio Breast Cancer Symposium.

Also Read: Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

“Triple-negative breast cancer is a highly aggressive disease with a poor prognosis and 5-year survival rate of just 15% in advanced stages. There remains an urgent need for new treatment options, particularly ...